Guggenheim Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $35

Benzinga · 2d ago
Guggenheim analyst Paul Jeng initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $35.